Adverum is a gene therapy company committed to discovering and developing novel medicines that can offer life-changing benefits to patients living with rare diseases or diseases of the eye who currently have limited or burdensome treatment options. We have a robust pipeline that includes product candidates to treat wet AMD, A1AT deficiency, and hereditary angioedema. Leveraging our next-generation adeno-associated virus (AAV)-based directed evolution platform, we are generating product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. In addition, we have collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Our focus on the patient is supported by clinical development expertise and core capabilities in vector optimization, process development, manufacturing, and assay development.
Adverum Biotechnologies NASDAQ: ADVM
$2.7502/21/174:00 p.m. ET
Data provided by Nasdaq.
Minimum 15 minutes delayed.